uniQure (NASDAQ:QURE) Sets New 52-Week High – Here’s What Happened

Shares of uniQure (NASDAQ:QURE) reached a new 52-week high on Tuesday . The stock traded as high as $18.18 and last traded at $18.18, with a volume of 29630 shares. The stock had previously closed at $17.22.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Royal Bank of Canada lifted their price objective on uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Mizuho upped their price target on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 19th. Leerink Partners lifted their price objective on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. Finally, Guggenheim reiterated a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.88.

uniQure Stock Performance

The firm has a market capitalization of $860.80 million, a PE ratio of -3.56 and a beta of 0.89. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a 50-day moving average of $9.92 and a 200 day moving average of $7.45.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. Equities research analysts predict that uniQure will post -3.82 EPS for the current year.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.74% of the stock is owned by company insiders.

Institutional Investors Weigh In On uniQure

A number of hedge funds have recently made changes to their positions in QURE. RTW Investments LP bought a new position in shares of uniQure during the 3rd quarter valued at $49,000. China Universal Asset Management Co. Ltd. boosted its position in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares during the period. Atria Investments Inc bought a new position in shares of uniQure during the third quarter valued at about $53,000. Quarry LP purchased a new position in shares of uniQure in the third quarter worth about $58,000. Finally, Vanguard Personalized Indexing Management LLC increased its holdings in shares of uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,306 shares during the period. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.